



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:

Hesketh *et al.*

Appl. No.: 09/518,190

Filed: March 2, 2000

For: **Expression System for the
Secretion of Intracellular Proteins**

Confirmation No.: 4790

Art Unit: 1647

Examiner: Landsman, Roberts

Atty. Docket: 0623.0820001/LBB/JAH

**First Supplemental Information Disclosure Statement Under 37 C.F.R.
§ 1.97(c)**

Commissioner for Patents
PO Box 1450
Alexandria, VA 22313-1450

Sir:

Listed on accompanying Form PTO-1449 are documents that may be considered material to the examination of this application, in compliance with the duty of disclosure requirements of 37 C.F.R. §§ 1.56, 1.97 and 1.98. The numbering on this First Supplemental Information Disclosure Statement is a continuation of the numbering in Applicants' Information Disclosure Statement filed on August 29, 2000 in connection with the above-captioned application.

Where the publication date of a listed document does not provide a month of publication, the year of publication of the listed document is sufficiently earlier than the effective U.S. filing date and any foreign priority date so that the month of publication is not in issue. Applicants have listed publication dates on the attached PTO-1449 based on information presently available to the undersigned. However, the listed publication dates should not be construed as an admission that the information was actually published on the date indicated.

Applicants reserve the right to establish the patentability of the claimed invention over any of the information provided herewith, and/or to prove that this information may not be prior art, and/or to prove that this information may not be enabling for the teachings purportedly offered.

This statement should not be construed as a representation that a search has been made, or that information more material to the examination of the present patent application does not exist. The Examiner is specifically requested not to rely solely on the material submitted herewith.

Filing under 37 C.F.R. § 1.97(c). This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection, or Notice of Allowance, or an action that otherwise closes prosecution in the application.


Attached is our PTO-2038 Credit Card Payment Form in the amount of \$180.00 in payment of the fee under 37 C.F.R. § 1.17(p).

It is respectfully requested that the Examiner initial and return a copy of the enclosed PTO-1449, and indicate in the official file wrapper of this patent application that the documents have been considered.

The U.S. Patent and Trademark Office is hereby authorized to charge any fee deficiency, or credit any overpayment, to our Deposit Account No. 19-0036.

Respectfully submitted,


STERNE, KESSLER, GOLDSTEIN & FOX P.L.L.C.



Lawrence-B. Bugaisky
Attorney for Applicants
Registration No. 35,086

Date: March 16, 2004

1100 New York Avenue, N.W.
Washington, D.C. 20005-3934
(202) 371-2600
241747v1



FORM PTO-1449

ATTY. DOCKET NO.

0623.0820001

APPLICATION NO.

09/518,190

FIRST NAMED INVENTOR

Hesketh *et al.*

FILING DATE

March 2, 2000

ART UNIT

1646

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA2						
	AB2						
	AC2						
	AD2						
	AE2						
	AF2						
	AG2						
	AH2						
	AI2						
	AJ2						
	AK2						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL2						Yes No
	AM2						Yes No
	AN2						Yes No
	AO2						Yes No
	AP2						Yes No


OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>10</u>	Lia, Y., <i>et al.</i> , "Processing of fusion protein by endoprotease in COS-1 cells for secretion of mature peptide by using a chimeric expression vector," <i>Proc. Natl. Acad. Sci. USA</i> 90:8957-8961, National Academy Science, (1993)
	AS	<u>10</u>	
	AT	<u>10</u>	

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.



FORM PTO-1449

ATTY. DOCKET NO.
0623.0820001APPLICATION NO.
09/518,190FIRST NAMED INVENTOR
Hesketh *et al.*FILING DATE
March 2, 2000ART UNIT
1646

INFORMATION DISCLOSURE STATEMENT

U.S. PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB-CLASS	FILING DATE
	AA1						
	AB1						
	AC1						
	AD1						
	AE1						
	AF1						
	AG1						
	AH1						
	AI1						
	AJ1						
	AK1						

FOREIGN PATENT DOCUMENTS

EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUB-CLASS	TRANSLATION
	AL1						Yes No
	AM1						Yes No
	AN1						Yes No
	AO1						Yes No
	AP1						Yes No

OTHER (Including Author, Title, Date, Pertinent Pages, etc.)

	AR	<u>9</u>	
	AS	<u>9</u>	Demolder, J., <i>et al.</i> , "Efficient synthesis of secreted murine interleukin-2 by <i>Saccharomyces cerevisiae</i> : influence of 3'-untranslated regions and codon usage," <i>Elsevier Science Publishers B.V., Gene</i> 111 207-213, (1992)
	AT	<u>9</u>	Yang, C., <i>et al.</i> , "The Expression and Characterization of Human Recombinant Proinsulin-Like Growth Factor II and a Mutant That Is Defective in the O-Glycosylation of Its E Domain," <i>Endocrinology USA</i> 137:2766-2773, The Endocrine Society, (1996)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.